Egetis Therapeutics AB (LTS:0ABW) Moat Score: 0/10 (As of Jul. 07, 2026)


LTS:0ABW Egetis Therapeutics AB LTS:0ABW
59 GF Score
Price kr5.91
GF Value kr5.61
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Moat Score?

Egetis Therapeutics AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Egetis Therapeutics AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Egetis Therapeutics AB might have No Moat - No discernible moat.

Egetis Therapeutics AB  (LTS:0ABW) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Egetis Therapeutics AB Moat Score Related Terms

LTS:0ABW
59GF Score
Egetis Therapeutics AB LTS:0ABW
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr5.91 is trading 5.3% above its estimated GF Value™ of kr5.61. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for LTS:0ABW:

  • Moat Score: 0
  • GF Value™: kr5.61 vs. price of kr5.91 (5.3% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
59GF Score

Get the complete analysis for LTS:0ABW

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.91
Price
kr5.61
GF Value